Skip to main content

Advertisement

Table 1 Clinical characteristics of patients with aberrant expressed miR-362-5p

From: MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia

Variables Low expression High expression P value
Number 112 112  
Sex, n (%) 60 (53.6) 71 (63.4) 0.175
Age, years# 45.50 [33.00, 59.00] 50.50 [41.25, 62.00] 0.048
WBC, 109/l# 18.60 [4.79, 64.65] 28.30 [5.80, 93.55] 0.301
Hemoglobin, /l# 79.50 [66.00, 95.00] 88.50 [67.00, 105.25] 0.061
PLT, 109/l# 38.50 [22.75, 77.25] 46.50 [25.00, 109.50] 0.141
Blast, %# 69.00 [54.00, 79.62] 71.50 [48.38, 82.62] 0.920
FAB subtype, n (%) 0.904
 M0 9 (8.0) 11 (9.8)
 M1 12 (10.7) 11 (9.8)
 M2 47 (42.0) 50 (44.6)
 M4 14 (12.5) 9 (8.0)
 M5 28 (25.0) 28 (25.0)
 M6 2 (1.8) 3 (2.7)
Genes mutation, n (%)  
 FLT3-ITD 19 (17.0) 24 (21.4) 0.498
 CEBPADM& 14 (12.5) 17 (15.2) 0.699
 NPM1 21 (18.8) 33 (29.5) 0.085
 DNMT3A 10 (8.9) 12 (10.7) 0.823
 IDH1 7 (6.2) 12 (10.7) 0.338
 IDH2 11 (9.8) 19 (17.0) 0.169
 CR rates 76 (67.9) 63 (56.2) 0.098
  1. WBC white blood cell counts, PLT platelet counts, DM& double allele mutations
  2. #Median (interquartile)